Vildagliptin is an anti-diabetic drug of the dipeptidyl Peptidase-4 (DPP-4) inhibitor class of drug. The biological half-life of the drug is 1 .5 hours. Elimination half life is less so we can consider improving the bioavailability of the drug. The present research work was to develop sustained release tablets of vildagliptin to achieve a sustained drug release with reduced frequency of drug administration reduced side effects and improved patient compliance. Sustained Release tablets of vildagliptin by using different polymers like Carbopol and Eudragit grades. Drug Excipient Compatibility study was performed through FTIR revealed that there no interaction between drug and polymers. The tablets were prepared by wet granulation technique. The prepared SR Matrix tablets were evaluated for various physico chemical parameters. All the formulations resulted in acceptable Pharmacopoeia limits. In-vitro drug release studies (USP dissolution rate test apparatus II, 50 rpm, 370C ±0.50C) using 0.1N hydrochloric acid(1.2 PH) for first 2hrs and phosphate buffer (PH 6.8) as a dissolution medium (900ml) for the next 10 hrs. Among all the formulation F-2 shows better result upto 12 hours of the drug release was found to be 99.37±0.87 % so it’s an Optimized formulation. Release kinetics were applied to optimized formulation shows that the pattern of release was Zero order (R2 = 0.9917).